CytoQuest CR Liquid Biopsy Helps Tumor Precision Medicine - CellSearch Excellence Alternative

In cancer diagnosis and treatment, doctors often rely on invasive biopsy and non-invasive imaging to track tumor size, spread, and response to treatment. However, with the deepening of research on cancer, scientists have found that there are certain limitations in organizing biopsy in the diagnosis and treatment of cancer, and it will also bring trauma to patients. The emergence of liquid biopsy broke this deadlock and was selected as the “Top Ten Breakthrough Technology of 2015” by MIT Technology Review magazine.

Although tumor biopsy sections are the gold standard and the main source of specimens, access is difficult and the disease progression cannot be tracked. At present, the more in-depth liquid biopsy techniques include Circulating Tumor Cells (CTCs) and ctDNA. Both technologies can provide real-time monitoring of tumor progression and provide a scientific basis for personalized tumor diagnosis and treatment.

Compared with circulating ctDNA and exosomes, CTC analysis has obvious advantages as a liquid biopsy method, which is oriented to living cells, not only a simple vector for individual tumor biomarkers, but also a living tumor cell entity. Information on mutations and drug susceptibility changes, emerging tumor subcloning information that can be targeted by specific drugs. From this point of view, CTC molecular characteristics can provide the basic composition of personalized cancer treatment, based on the characteristics of CTC molecules in the changing tumor molecular map and the drug sensitivity patterns of these cells to make treatment decisions.

CTCs research has been a very hot research topic for decades. According to statistics, there are more than 16900 CTCs-related literatures searchable on Pubmed from October 1965 to October 2015. However, despite the publication of so many papers, there are still no good CTCs testing equipment and clinical application guidelines. The main reason is that it is very difficult to obtain CTCs due to the small number. How to effectively separate and enrich CTCs has been a major challenge in the fields of medical, clinical, biotechnology and biomedical device manufacturing. CTCs capture technology mainly includes biomolecular recognition, nanostructure recognition, size recognition, etc. More than 50 CTCs detection technologies have been reported.

Taiwan's Acnova's CytoQuestTM CR is the latest generation of circulating tumor cell detection and collection systems that outperforms the existing Johnson & Johnson-CellSearch. Compared to CellSearch, CytoQuestTM CR performs a variety of downstream analyses, including immunofluorescence analysis, FISH for chromosome recombination, and single-cell sequencing.

*For more details on the CytoQuestTM CR system, please visit:

Http://

At present, the CytoQuestTM CR system has passed the CE-IVD certification of the European Union, and its cell counting application products have also obtained FDA certification, which can be used as one of the diagnostic indicators for clinical breast cancer, prostate cancer and intestinal cancer. For translation and clinical medical research, CytoQuestTM CR is a powerful aid that helps identify and track cancer cell changes and metastases. It opens up new horizons in clinical diagnostics and pharmaceuticals, and powers tumors. Precision medicine.

Abnova is a global biotechnology company that combines world-class biotechnology with Taiwan's IT industry management experience. In addition to providing the unique CytoQuestTM CR system, it also focuses on high-throughput protein expression and antibody production. Abnova's tens of thousands of recombinant proteins and antibodies produced by genomics have greatly expanded the field of vision and diversity of biological reagent applications. . At the same time, Abnova continues to expand its product line for system applications, including paired antibodies, ELISA kits, in situ hybridization fluorescent probes, non-expressed protein quantification, and applications for protein translation research, diagnostics, and pharmaceutical companies. Basic in vitro diagnostic equipment. As Abnova's regional agent in China, Aimei Technology Co., Ltd., with its rich professional experience, will continue to provide Abnova's quality products and technical services to regional customers in China. Welcome to the official website of Amy Jie for more information. If you are interested in the above products, please call the free customer line 400-6800-868 to contact Aimei Technology Co., Ltd. for product information and complete experimental solutions.